Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Símbolo de cotizaciónVCYT
Nombre de la empresaVeracyte Inc
Fecha de salida a bolsaOct 30, 2013
Director ejecutivoMr. Marc A. Stapley
Número de empleados824
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 30
Dirección6000 Shoreline Court, Suite 300
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94080
Teléfono16502436300
Sitio Webhttps://www.veracyte.com/
Símbolo de cotizaciónVCYT
Fecha de salida a bolsaOct 30, 2013
Director ejecutivoMr. Marc A. Stapley
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos